This report analyzes the worldwide markets for Anticoagulants in Millions of US$ by the following Product Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecastsare provided for the period of 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 45 companies including many key and niche players such as Bayer Healthcare AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eisai Inc., GlaxoSmithKline plc, LEO Pharmaceutical Products, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi, Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
Table of Contents
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions And Scope of Study
II. EXECUTIVE SUMMARY
1. OUTLOOK
A Prelude
Anticoagulants- An Evolving Market
Injectables or Oral Drugs - The Road Ahead
Conventional Oral Drugs to Face the Heat Too
New Drugs yet to Gain Mainstream Status
Sizing the Market
2. INDUSTRY OVERVIEW
Issues with Traditional Drugs Fueling the Hunt for New Anticoagulants
New Therapies: Need of the Hour
Drug Advancements Drive Anticoagulant Market
Niche Markets - The New Target for Drug Makers
Anticoagulant Therapy in IPF: Reduces Mortality Risk
Anticoagulants to Lose UA/AMI Markets to Antiplatelets
An Opportunity to Grow Further
Warfarin & Heparins: The Former Market Leaders
Generics Drugs Prevail in the Anticoagulant Market
Concern Over Underutilization of Warfarin
Novel Oral Anticoagulants to Turbo-Charge Market Growth
Hurdles Exist for New Oral Agents
The Merits and Demerits of New Age Anticoagulants
Lack of Adequate Trials Mar Pediatric Anticoagulants Market
Improved Anticoagulant Agents for Children Group
Growing Demand for Self-Testing
LMWHs Ease Outpatient Management
Novel Heparins Enhance Market Potential
A Focus on Failed or Withdrawn Agents in Recent Past
Idraparinux and Idrabiotaparinux Sodium - Sanofi's Discontinued Agents
Lack of Statistical Significance Leads to Culmination of Tecarfarin's Development
Sofigatran - A Failed Agent from Mitsubishi Tanabe Pharma
3. ORAL ANTICOAGULANT AGENTS
Traditional Oral Anticoagulants
Warfarin
Advantages and Alternatives
Side Effects
Limitations
Coumadin - The Branded Warfarin
Novel Oral Anticoagulants
Dabigatran Etexilate (Pradaxa)
Table 1: Pradaxa and Warfarin - A Comparative Study
Approved Indications for Pradaxa in Select Regions
Rivaroxaban (Xarelto)
Approved Indications for Xarelto in Select Regions
Xarelto Patent Expiration in Various Regions
Apixaban (Eliquis)
Betrixaban
Comparison of Select Approved and Pipeline Anticoagulant Agents in a Nutshell
Market Dynamics
New Oral Drugs More Efficacious In Reducing Stroke
New Generation Anticoagulants Enter the Market, Warfarin Comes Under Pressure
Oral Anticoagulants Market to Witness Intense Competition
Pradaxa- A High Potential Replacement to Warfarin
Packaging May Hurt Pradaxa's Prospects
New Oral Drugs in Various Indications
Emerging Targets in the Anticoagulation Space
Daiichi Sankyo Upbeat on Prospects of Edoxaban
ELIQUIS' FDA Approval Faces Further Delays
The ARISTOTLE Trial
Eliquis - More Promising than Existing Oral Anticoagulants
Competitors Capitalize on Delay in Eliquis' Approval
Do New Oral Anticoagulants Circumvent Issues with Conventional Drugs?
Hemostatic Agents for Reversing Action of New Oral Drugs - An Area Demanding Active Research
4. INJECTABLE ANTICOAGULANTS
Injectable Anticoagulants- An Insight
Heparin - The Back Bone of Injectable Anticoagulants
Unfractionated Heparin
Advantages and Alternatives
Limitations
Low Molecular Weight Heparins
Indications
Advantages
Contraindications
Side Effects
Caution
Costs
Impediments
A Focus on Select Heparin Based Injectables
Lovenox/Clexane (enoxaparin)
Approved Indications for Lovenox
Advantages and Alternatives
Table 2: World Lovenox Sales by Geographic Region (2009-2011): Breakdown of Value Sales in US$ Million for Western Europe, US, Emerging Markets and Others (includes corresponding Graph/Chart)
Fragmin (dalteparin sodium)
Approved Indications for Fragmin Use
Contraindications
Precautions
Fraxiparine (nadroparin)
Innohep (tinzaparin)
Contraindications
Side Effects
Other Serious Adverse Events Associated with Innohep
Precautions
Normiflo (ardeparin)
Clivarine (reviparin)
Table 3: Summary of Available LMWHs
A Comparison of FDA Approved Indications for Select Injectable LMWHs - Lovenox, Innohep and Fragmin
Non-Heparin Anticoagulant Injectables - An Overview
Arixtra (fondaparinux)
Contraindications
Market and Market Participants
Angiomax (bivalirudin)
Advantages
Contraindications
Side Effects
Argatroban/Novastan
Side Effects
Precautions
Refludan (lepirudin)
Orgaran (danaparoid Sodium)
Contraindications
Side Effects
Caution
Precaution
A Comparative Analysis of Various Direct Thrombin Inhibitors
5. A COMPARATIVE STUDY OF ANTICOAGULANT THERAPIES
A Comparative Study of Warfarin Against LMWHs
A Comparative Study of LMWH Against UFH
A Comparative Study of New Anticoagulants/ Anticoagulant Candidates Against Warfarin
A Comparative Study of Heparin Against Angiomax
A Comparative Study of Arixtra Against UFH and LMWH
A Comparative Study of Angiomax Against UFH and LMWH
6. AREAS OF INDICATION
Indications for Anticoagulant Use
Venous/DVT Thrombosis Indications
Desired Anticoagulant Qualities for DVT Indications
Venous Thromboembolism
Deep Vein Thrombosis
Pulmonary Embolism
Orthopedic (Hip or Knee Replacement) Surgery
General Surgery
Cancer
Arterial Thrombosis Indications
Arterial Thrombosis
Acute Coronary Syndromes
Atrial Fibrillation
Unstable Angina
List of Approved Anticoagulants for Unstable Angina
Myocardial Infraction
Non ST-Segment Elevation MI
List of Approved Anticoagulants for Non-ST Segment Elevation Myocardial Infarction
Heparin Induced Thrombocytopenia with Thrombosis (HITTS)
Other Indications
Hemodialysis
7. DRUG DEVELOPMENT PIPELINE
Select Anticoagulants in Clinical Development
Anticoagulant Therapies in Development Stage
Idraparinux - Sanofi
0673 - Sanofi
MER-102
Semuloparin Sodium (AVE 5026)
8. PRODUCT INTRODUCTIONS/APPROVALS
Mitsubishi Pharma Introduces Argatroban in the UK
Bayer Obtains Canadian Approval for Xarelto in the Treatment of Deep Vein Thrombosis
Pradaxa Gains Regulatory Approval in Japan for Prevention of Stroke
Pfizer and Bristol-Myers Launch ELIQUIS Black Triangle Drug
ELIQUIS(r) Receives Approval in EU in Prevention of VTE
Xarelto Obtains Approval in UK
Xarelto Receives FDA Approval for Prevention of DVT
Eisai Launches Warfarin Granules 0.2% in Japan
Amphastar Receives FDA Approval for ANDA of Enoxaparin Sodium Injection
Boehringer Ingelheim Obtains EU Approval for Pradaxa in AF
Daiichi Sankyo Introduces Edoxaban Tablets in Japan
9. PRODUCT INTRODUCTIONS/APPROVALS IN RECENT PAST- A PERSPECTIVE BUILDER
GSK Receives EU Approval for Arixtra(r)
Pradaxa Receives FDA Approval
Canyon Pharmaceuticals Introduces Iprivask
Teva Receives FDA's Tentative Approval for Argatroban
TrimGen Receives FDA 510(k) Approval for Marketing eQ- PCR(tm) LC Warfarin Genotyping Kit
Lundbeck Launches ATryn(r) Commercially in the US
The Medicines Co Receives European Approval for Angiox (Bivalirudin)
10. RECENT INDUSTRY ACTIVITY
FDA Issues Complete Response Letter for Eliquis's New Drug Application
FDA Issues Complete Response Letter to Rivaroxaban's (Xarelto) NDA for ACS
US FDA Extends Date for Eliquis' New Drug Application
Pradaxa(r) Receives NICE Recommendation
BioInvent and ThromboGenics Discontinue Development of TB-402
Watson Receives Stay Order on Preliminary Injunction
FDA Assigns Priority Review for Xarelto Supplemental NDA
Portola Pharmaceuticals Re-Acquires Rights to Betrixaban
FDA Accepts New Drug Application for ELIQUIS(r)
Astellas Pharma Halts Development of Anticoagulant
Sanofi-Aventis Changes Name to Sanofi
11. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER
Boehringer Ingelheim Expands Manufacturing Capacity at Ingelheim
Sagent Pharmaceuticals Secures FDA Approval for Heparin Sodium Injection
Biomet Acquires Cytosol Laboratories
Portola Inks $470 M Agreement with Merck for Phase II Anticoagulant
Catalent Pharma Inks Strategic Alliance Deal with Endotis Pharma
Nuvelo and ARCA biopharma Merge
12. FOCUS ON SELECT GLOBAL PLAYERS
Bayer Healthcare AG (Germany)
Boehringer Ingelheim (Germany)
Bristol-Myers Squibb Company (USA)
Eisai Inc. (USA)
GlaxoSmithKline plc (UK)
LEO Pharmaceutical Products (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Pfizer Inc. (USA)
Sanofi (France)
Teva Pharmaceutical Industries Ltd (Israel)
Teva Pharmaceuticals USA (USA)
13. GLOBAL MARKET PERSPECTIVE
Table 4: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 5: World Historic Review for Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 6: World 15-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Table 7: World Recent Past, Current & Future Analysis for Oral Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 8: World Historic Review for Oral Anticoagulants by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 9: World 15-Year Perspective for Oral Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Table 10: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 11: World Historic Review for Injectable Anticoagulants by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 12: World 15-Year Perspective for Injectable Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Table 13: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 14: World Historic Review for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 15: World 15-Year Perspective for Injectable Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current & Future Analysis for Unfractionated Heparin by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 17: World Historic Review for Unfractionated Heparin by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 18: World 15-Year Perspective for Unfractionated Heparin by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Table 19: World Recent Past, Current & Future Analysis for Low Molecular Weight Heparin by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 20: World Historic Review for Low Molecular Weight Heparin by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 21: World 15-Year Perspective for Low Molecular Weight Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A. Market Analysis
Outlook
Atrial Fibrillation - A Key Risk Factor
Price Controls
US Anticoagulants Market
FDA Approved Anticoagulants
Table 22: Novel Drugs/Drug Candidates in the US Anticoagulants Market
Table 23: US Vitamin K Antagonists Market (2011): Percentage Breakdown of Value Sales by Drug- Coumadin, Warfarin Generics and Others (includes corresponding Graph/Chart)
Table 24: US Direct Thrombin (II) Inhibitors Market (2011): Percentage Breakdown of Value Sales by Drug - Pradaxa, Angiomax, Argatroban, Refludan and Others (includes corresponding Graph/Chart)
Table 25: US Market for Xarelto (2011): Percentage Share Breakdown of Sales by Indication- Atrial Fibrillation and DVT Prevention in Surgery (includes corresponding Graph/Chart)
Payers Keen on New Therapies
Pradaxa's Initial Performance Commendable, Conventional AVK Products Still Dominate
US Heparin Market
Hinging on Market Opportunities
Generics - Threatening Branded Anticoagulants
List of Patent Protected Anticoagulants in the US
Generic Competition Threatens Sanofi's Lovenox
Table 26: Leading Players in the US Enoxaparin Sodium Market (2011): Percentage Breakdown of Sales for Sandoz and Sanofi (includes corresponding Graph/Chart)
Table 27: US Enoxaparin Sodium Market by Sector (2011): Percentage Breakdown of Sales for Institutional and Retail Sectors (includes corresponding Graph/Chart)
Ignorance - A Major Hindrance
Future Challenges and Growth Drivers
US Emerging Anticoagulant Market
Product Introductions/Approvals
Recent Industry Activity
Focus on Select Players
B. Market Analytics
Table 28: US Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 29: US Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 30: US 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
2. JAPAN
A. Market Analysis
Outlook
Anticoagulants Market in Japan
Rising Incidence of Pulmonary Thromboembolism
Product Introductions/Approvals
Recent Industry Activity
Focus on Select Players
Regional Player
B. Market Analytics
Table 31: Japanese Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 32: Japanese Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 33: Japanese 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
3. EUROPE
A. Market Analysis
Outlook
Market in High Need of an Ideal Therapy
Product Introductions/Approvals
B. Market Analytics
Table 34: European Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 35: European Historic Review for Anticoagulants by Geographic Region / Country - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 36: European 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Table 37: European Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 38: European Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 39: European 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
3a. FRANCE
A. Market Analysis
Outlook
Recent Industry Activity
Focus on Select Players
B. Market Analytics
Table 40: French Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 41: French Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 42: French 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
3b. GERMANY
A. Market Analysis
Outlook
Market Drivers for Injectable Anticoagulants
Anticoagulants Growth Drive European POC Testing Market
Focus on Select Players
B. Market Analytics
Table 43: German Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 44: German Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 45: German 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
3c. ITALY
A. Market Analysis
Outlook
B. Market Analytics
Table 46: Italian Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 47: Italian Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 48: Italian 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
3d. THE UNITED KINGDOM
A. Market Analysis
Outlook
Product Introductions/Approvals
Recent Industry Activity
Focus on Select Players
B. Market Analytics
Table 49: UK Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 50: UK Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 51: UK 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
3e. SPAIN
A. Market Analysis
Outlook
B. Market Analytics
Table 52: Spanish Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 53: Spanish Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 54: Spanish 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
3f. REST OF EUROPE
A. Market Analysis
Outlook
Focus on Select Player
B. Market Analytics
Table 55: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 56: Rest of Europe Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 57: Rest of Europe 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
4. REST OF WORLD
A. Market Analysis
Outlook
Heparin Market in China Gains Momentum
Product Introduction/Approval
Focus on Select Player
B. Market Analytics
Table 58: Rest of World Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 59: Rest of World Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 60: Rest of World 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Anticoagulants published by Global Industry Analysts, Inc. in October 1, 2012. This report consists of Pages: 434 and the price starts from US $ 4950.
The contents of this page may be different from the latest version. Please contact us for details.
